U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H17N3S
Molecular Weight 211.3285
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRAMIPEXOLE

SMILES

CCCN[C@@]1([H])CCc2c(C1)sc(=N)[nH]2

InChI

InChIKey=FASDKYOPVNHBLU-ZETCQYMHSA-N
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf

Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. Pramipexole is used for the treatment of signs and symptoms of idiopathic Parkinson's disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [EC50]
27.0 nM [EC50]
15.0 nM [EC50]
4.81 µM [IC50]
5.37 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

8.6762881E11
Primary
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

8.6762881E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.268 ng/mL
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.29 ng × h/mL
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.2 h
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources: Page: p.740
Disc. AE: Hallucination, Hypotension...
AEs leading to
discontinuation/dose reduction:
Hallucination (1.3%)
Hypotension (0.5%)
Peripheral edema (0.5%)
Sources: Page: p.740
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Disc. AE: Hallucinations, Sleepiness...
AEs leading to
discontinuation/dose reduction:
Hallucinations (4.3%)
Sleepiness (3%)
Dizziness (2.5%)
Memory loss (1.2%)
Paranoia (0.6%)
Sources: Page: p.727
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
DLT: Drowsiness, Muscle spasms...
Dose limiting toxicities:
Drowsiness (3.6%)
Muscle spasms (1.8%)
Insomnia (1.8%)
Vertigo (1.8%)
Ankle swelling (1.8%)
Hallucination (3.6%)
Nausea (1.8%)
Sources: Page: p.128
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Disc. AE: Nausea, Hallucination...
AEs leading to
discontinuation/dose reduction:
Nausea (0.6%)
Hallucination (1%)
Peripheral edema (0.8%)
Abdominal pain upper (0.6%)
Myocardial infarction (0.6%)
Pneumonia (0.6%)
Vomiting (0.6%)
Sources: Page: p.740
AEs

AEs

AESignificanceDosePopulation
Hypotension 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources: Page: p.740
Peripheral edema 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources: Page: p.740
Hallucination 1.3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources: Page: p.740
Paranoia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Memory loss 1.2%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Dizziness 2.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Sleepiness 3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Hallucinations 4.3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Ankle swelling 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Insomnia 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Muscle spasms 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Nausea 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Vertigo 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Drowsiness 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Hallucination 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Abdominal pain upper 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Myocardial infarction 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Nausea 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Pneumonia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Vomiting 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Peripheral edema 0.8%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Hallucination 1%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
PubMed

PubMed

TitleDatePubMed
Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
2001
Economic and health-related quality of life considerations of new therapies in Parkinson's disease.
2001
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
2001
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.
2001 Apr 6
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
2001 Feb
Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.
2001 Jul
Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
2001 Jun 12
Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.
2001 Jun 29
Does combined treatment with novel antidepressants and a dopamine D3 receptor agonist reproduce cocaine discrimination in rats?
2001 Nov-Dec
Daytime sleepiness and other sleep disorders in Parkinson's disease.
2001 Oct 23
Locomotor hypoactivity and motor disturbances--behavioral effects induced by intracerebellar microinjections of dopaminergic DA-D2/D3 receptor agonists.
2001 Sep-Oct
Restless legs syndrome in the older adult: diagnosis and management.
2002
Sleep disorders in Parkinson's disease: epidemiology and management.
2002
DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
2002
Choosing the right dopamine agonist for patients with Parkinson's disease.
2002
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
2002
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
2002 Apr 3
[Pramipexole in Parkinson disease. Results of a treatment observation].
2002 Aug
Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
2002 Aug
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
2002 Dec 24
[Rapid-eye-movement sleep disorders in Parkinson's disease].
2002 Feb
Long-term studies of dopamine agonists.
2002 Feb 26
Neuroprotection and dopamine agonists.
2002 Feb 26
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.
2002 Jan 23-30
Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease.
2002 Jan-Feb
Pergolide in the treatment of patients with early and advanced Parkinson's disease.
2002 Jan-Feb
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
2002 Jun
Sleep attacks in patients taking dopamine agonists: review.
2002 Jun 22
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
Dopamine agonist monotherapy in Parkinson's disease.
2002 Nov 30
Neuroprotection in idiopathic Parkinson's disease.
2002 Oct
Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice.
2002 Oct
Effect of daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens.
2002 Oct
Combination of two different dopamine agonists in the management of Parkinson's disease.
2002 Sep
Review: selegiline improves symptoms and levodopa is better than pramipexole for motor function in untreated Parkinson disease.
2002 Sep-Oct
Advances in the pharmacological management of Parkinson disease.
2003
Pramipexole in comparison to l-dopa: a neuropsychological study.
2003 Apr
Piribedil-induced sleep attacks in Parkinson's disease.
2003 Feb
Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
2003 Feb
Slowing Parkinson's disease progression: recent dopamine agonist trials.
2003 Feb 11
Loss of color vision during long-term treatment with pramipexole.
2003 Jan
Sleepwalking and sleep terrors in prepubertal children: what triggers them?
2003 Jan
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
2003 Jul
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
2003 Jul
Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment.
2003 Jun
Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
2003 Jun
The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption--a nation-wide perspective in Sweden.
2003 Jun
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
2003 May
Current treatment options for restless legs syndrome.
2003 Oct
Clinical strategies to prevent and delay motor complications.
2003 Sep 23
Patents

Sample Use Guides

Dosages should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days.
Route of Administration: Oral
Pramipexole suppressed H2O2-induced ARPE-19 cell death in vitro at concentrations of 10(-6) M or higher.
Name Type Language
PRAMIPEXOLE
INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
U-98528E
Code English
SUD-919CL2Y
Code English
SUD919CL2Y
Code English
PRAMIPEXOLE [USAN]
Common Name English
NSC-760426
Code English
PRAMIPEXOLE [WHO-DD]
Common Name English
PRAMIPEXOLE [INN]
Common Name English
PRAMIPEXOLE [VANDF]
Common Name English
PRAMIPEXOLE [MI]
Common Name English
PRAMIPEXOL
Common Name English
Classification Tree Code System Code
WHO-VATC QN04BC05
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
LIVERTOX 789
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
NDF-RT N0000000117
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
FDA ORPHAN DRUG 252007
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
NCI_THESAURUS C265
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
WHO-ATC N04BC05
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
NDF-RT N0000175768
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
Code System Code Type Description
PUBCHEM
119570
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
DRUG BANK
DB00413
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
CAS
104632-26-0
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
WIKIPEDIA
PRAMIPEXOLE
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
DRUG CENTRAL
2233
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
NCI_THESAURUS
C66456
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
RXCUI
746741
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY RxNorm
LACTMED
Pramipexole
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
EPA CompTox
104632-26-0
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
IUPHAR
953
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
FDA UNII
83619PEU5T
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
INN
6227
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
HSDB
8253
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
MESH
C061333
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
MERCK INDEX
M9095
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY Merck Index
EVMPD
SUB09990MIG
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY
ChEMBL
CHEMBL301265
Created by admin on Fri Jun 25 22:07:19 UTC 2021 , Edited by admin on Fri Jun 25 22:07:19 UTC 2021
PRIMARY